



3425 Corporate Way



Patient: SAMPLE **PATIENT**


DOB: Sex: MRN: Duluth, GA 30096


2200 GI Effects™ Comprehensive Profile - Stool




INFECTION Dientamoeba fragilis Blastocystis spp.









See individual sections for detailed results





^{**}The total number of Commensal Bacteria (PCR) that are out of reference ranges for this individual.







Beta-glucuronidase

Tests were developed and their performance characteristics determined by Genova Diagnostics. Unless otherwise noted with ◆, the assays have not been cleared by the U.S. Food and Drug Administration.


2,297

368-6,266 U/g

^{*}Total value is equal to the sum of all measurable parts.

[†]These results are not represented by quintile values.

Methodology: DNA by PCR



The gray-shaded portion of a quintile reporting bar represents the proportion of the reference population with results below detection limit.

Commensal results and reference range values are displayed in a computer version of scientific notation, where the capital letter "E" indicates the exponent value (e.g., 7.3E6 equates to 7.3 x 10° or 7,300,000).

The Firmicutes/Bacteroidetes ratio (F/B Ratio) is estimated by utilizing the lowest and highest values of the reference range for individual organisms when patient results are reported as <DL or >UL.



Gastrointestinal Microbiome**

Methodology: Culture/MALDI-TOF MS, Automated and Manual Biochemical Methods, Vitek® 2 System Microbial identification and Antibiotic susceptibility

Human microflora is influenced by environmental factors and the competitive ecosystem of the organisms in the GI tract. Pathogenic significance should be based upon clinical symptoms.


Microbiology Legend NG NP PP Ρ No Growth Non-**Potential** Pathogen Pathogen Pathogen

Additional Bacteria

Non-Pathogen: Organisms that fall under this category are those that constitute normal, commensal flora, or have not been recognized as etiological agents of disease.

Potential Pathogen: Organisms that fall under this category are considered potential or opportunistic pathogens when present in heavy growth. Pathogen: The organisms that fall under this category have a wellrecognized mechanism of pathogenicity in clinical literature and are

considered significant regardless of the quantity that appears in the culture.






Additional Bacteria

alpha haemolytic Streptococcus

Bacteriology (Culture)






Mycology (Culture)

Candida species





KOH Preparation for Yeast

Methodology: Potassium Hydroxide (KOH) Preparation for Yeast

Potassium Hydroxide (KOH) Preparation for Yeast

These yeast usually represent the organisms isolated by culture. In the presence of a negative yeast culture, microscopic yeast may reflect organisms not viable enough to grow in culture. The presence of yeast on KOH prep should be correlated with the patient's symptoms. However, moderate to many yeast suggests yeast overgrowth.

Result

KOH Preparation, stool

Few Yeast Present

The result is reported as the amount of yeast seen microscopically:

Rare: 1-2 per slide

Few: 2-5 per high power field (HPF)

Moderate: 5-10 per HPF Many: >10 per HPF

^{**} Indicates testing performed by Genova Diagnostics, Inc. 63 Zillicoa St., Asheville, NC 28801-0174 A. L. Peace-Brewer, PhD, D(ABMLI), Lab Director - CLIA Lic. #34D0655571 - Medicare Lic. #34-8475





Parasitology**

ID:

Microscopic O&P Results

Microscopic O&P is capable of detecting all described gastrointestinal parasites. The organisms listed in the box represent those commonly found in microscopic stool analysis. Should an organism be detected that is not included in the list below, it will be reported in the Additional Results section. For an extensive reference of all potentially detectable organisms, please visit www.gdx.net/product/gi-effects-comprehensive-stool-test

Genus/species	Result	
Nematodes - roundworms		
Ancylostoma/Necator (Hookworm)	Not Detected	
Ascaris lumbricoides	Not Detected	
Capillaria philippinensis	Not Detected	
Enterobius vermicularis	Not Detected	
Strongyloides stercoralis	Not Detected	
Trichuris trichiura	Not Detected	
Cestodes - tapeworms		
Diphyllobothrium latum	Not Detected	
Dipylidium caninum	Not Detected	
Hymenolepis diminuta	Not Detected	
Hymenolepis nana	Not Detected	
Taenia spp.	Not Detected	
Trematodes - flukes		
Clonorchis/Opisthorchis spp.	Not Detected	
Fasciola spp./ Fasciolopsis buski	Not Detected	
Heterophyes/Metagonimus	Not Detected	
Paragonimus spp.	Not Detected	
Schistosoma spp.	Not Detected	
Protozoa		
Balantidium coli	Not Detected	
Blastocystis spp.	Rare Detected	
Chilomastix mesnili	Not Detected	
Cryptosporidium spp.	Not Detected	
Cyclospora cayetanensis	Not Detected	
Dientamoeba fragilis	Moderate Detected	
Entamoeba coli	Not Detected	
Entamoeba histolytica/dispar	Not Detected	
Entamoeba hartmanii	Not Detected	
Entamoeba polecki	Not Detected	
Endolimax nana	Not Detected	
Giardia	Not Detected	
lodamoeba buetschlii	Not Detected	
Cystoisospora spp.	Not Detected	
Trichomonads (e.g. Pentatrichomonas)	Not Detected	
Additional Findings		
White Blood Cells	Not Detected	
Charcot-Leyden Crystals	Not Detected	
Other Infectious Findings		

3

One negative specimen does not rule out the possibility of a parasitic infection.

^{**} Indicates testing performed by Genova Diagnostics, Inc. 63 Zillicoa St., Asheville, NC 28801-0174

A. L. Peace-Brewer, PhD, D(ABMLI), Lab Director - CLIA Lic. #34D0655571 - Medicare Lic. #34-8475

Patient: SAMPLE PATIENT Page 6 ID:

Parasitology

PCR Parasitology - Protozoa**

Methodologies: DNA by PCR, Next Generation Sequencing

Organism	Result	Units		Expected Result
Blastocystis spp.	6.00e2	femtograms/microliter C&S stool	Detected	Not Detected
Cryptosporidium spp.	<4.87e2	genome copies/microliter C&S stool	Not Detected	Not Detected
Cyclospora cayetanensis	<2.65e2	genome copies/microliter C&S stool	Not Detected	Not Detected
Dientamoeba fragilis	6.40e2	genome copies/microliter C&S stool	Detected	Not Detected
Entamoeba histolytica	<1.14e3	genome copies/microliter C&S stool	Not Detected	Not Detected
Giardia	<1.57e2	genome copies/microliter C&S stool	Not Detected	Not Detected

Blastocystis spp. Reflex Subtyping

Type 1:	Not Detected	Type 4:	Not Detected	Type 7:	Not Detected
Type 2:	Detected	Type 5:	Not Detected	Type 8:	Not Detected
Type 3:	Not Detected	Type 6:	Not Detected	Type 9:	Not Detected

^{**} Indicates testing performed by Genova Diagnostics, Inc. 63 Zillicoa St., Asheville, NC 28801-0174

Additional Results

Methodology: Fecal Immunochemical Testing (FIT)

Expected Value Result Fecal Occult Blood◆ Negative Negative Color++ Green

Consistency†† Formed/Normal

Tests were developed and their performance characteristics determined by Genova Diagnostics. Unless otherwise noted with •, the assays have not been cleared by the U.S. Food and Drug Administration.

Zanulin Family Pontida

Methodology: EIA Zonulin Family Peptide, Stool	Zonami i animy i epude						
Methodology: EIA	Result	Reference Range	Zonulin Fam				
Zonulin Family Pentide, Stool	100.0	22.3-161.1 ng/mL	This test is for res				
Zenami rammy rapidae, etcer	100.0	22.0 101.1 119/1112	support on interpr				
			detect zonulin ¹ Th				

nily Peptide

esearch use only. Genova will not provide preting the test results. This test does not detect zonulin. The Scheffler paper suggests that the IDK kit may detect a zonulin family peptide, such as properdin. Genova's unpublished data demonstrated that the current IDK kit results were associated with stool inflammation biomarkers and an inflammation-associated dysbiosis profile.

The performance characteristics of Zonulin Family Peptide have been verified by Genova Diagnostics, Inc. The assay has not been cleared by the U.S. Food and Drug Administration.

Reference:

1. Scheffler L, et al. Widely Used Commercial ELISA Does Not Detect Precursor of Haptoglobin2, but Recognizes Properdin as a Potential Second Member of the Zonulin Family. Front Endocrinol. 2018;9:22.

A. L. Peace-Brewer, PhD, D(ABMLI), Lab Director - CLIA Lic. #34D0655571 - Medicare Lic. #34-8475

^{††}Results provided from patient input.

Macroscopic Exam for Worms **

Methodology: Macroscopic Evaluation

No larvae seen macroscopically.

	Add-o	n Testing
Methodology: EIA	Result	Expected Value
HpSA - <i>H. pylori</i>	Negative	Negative
Campylobacter spp.◆**	Negative	Negative
Clostridium difficile ◆**	Negative	Negative
Shiga toxin <i>E. coli◆**</i>	Negative	Negative
Fecal Lactoferrin◆**	Negative	Negative

HpSA (Helicobacter pylori stool antigen)

Helicobacter pylori is a bacterium which causes peptic ulcer disease and plays a role in the development of gastric cancer. Direct stool testing of the antigen (HpSA) is highly accurate and is appropriate for diagnosis and follow-up of infection.

Campylobacter spp.

Campylobacter jejuni is the most frequent cause of bacterial-induced diarrhea. While transmission can occur via the fecal-oral route, infection is primarily associated with the ingestion of contaminated and poorly cooked foods of animal origin, notably, red meat and milk.

Clostridium difficile

Clostridium difficile is an anaerobic, spore-forming gram-positive bacterium. After a disturbance of the gut flora (usually with antibiotics), colonization with Clostridium difficile can take place. Clostridium difficile infection is much more common than once thought.

Shiga toxin E. coli

Shiga toxin-producing *Escherichia coli* (STEC) is a group of bacterial strains that have been identified as worldwide causes of serious human gastrointestinal disease. The subgroup enterohemorrhagic *E. coli* includes over 100 different serotypes, with 0157:H7 being the most significant, as it occurs in over 80% of all cases. Contaminated food continues to be the principal vehicle for transmission; foods associated with outbreaks include alfalfa sprouts, fresh produce, beef, and unpasteurized juices.

Tests were developed and their performance characteristics determined by Genova Diagnostics. Unless otherwise noted with •, the assays have not been cleared by the U.S. Food and Drug Administration.

^{**} Indicates testing performed by Genova Diagnostics, Inc. 63 Zillicoa St., Asheville, NC 28801-0174

A. L. Peace-Brewer, PhD, D(ABMLI), Lab Director - CLIA Lic. #34D0655571 - Medicare Lic. #34-8475

Methodology: Vitek 2® System Microbial Antibiotic susceptibility, Manual Minimum Inhibition Concentration

Mycology Sensitivity

Azole Antifungals

Candida species	R	I	S-DD	S	NI
Fluconazole				0.5	
Voriconazole				<=0.008	

Non-absorbed Antifungals

Candida species	LOW INHIBITION	HIGH INHIBITION
Nystatin		

Natural Agents

Candida species	LOW INHIBITION	HIGH INHIBITIO
Berberine		
Caprylic Acid		
Garlic		
Undecylenic Acid		
Plant tannins		
Uva-Ursi		

Prescriptive Agents:

The R (Resistant) category implies isolate is not inhibited by obtainable levels of pharmaceutical agent.

The I (Intermediate) category includes isolates for which the minimum inhibition concentration (MIC) values usually approach obtainable pharmaceutical agent levels and for which response rates may be lower than for susceptible isolates.

The S-DD (Susceptible-Dose Dependent) category implies clinical efficacy when higher than normal dosage of a drug can be used and maximal concentration achieved.

The S (Susceptible) column implies that isolates are inhibited by the usually achievable concentrations of the pharmaceutical agent.

NI (No Interpretive guidelines established) category is used for organisms that currently do not have established guidelines for MIC interpretation.

Refer to published pharmaceutical guidelines for appropriate dosage therapy.

Nystatin and Natural Agents:

Results for Nystatin are being reported with natural antifungals in this category in accordance with laboratory guidelines for reporting sensitivities. In this assay, inhibition is defined as the reduction level on organism growth as a direct result of inhibition by a natural substance. The level of inhibition is an indicator of how effective the substance was at limiting the growth of an organism in an in vitro environment. High inhibition indicates a greater ability by the substance to limit growth, while Low Inhibition a lesser ability to limit growth. The designated natural products should be considered investigational in nature and not be viewed as standard clinical treatment substances.

Page 9

2200 GI Effects™ Comprehensive Profile - Stool

		Int	terpreta	tion At-a-0	Glance				
	Patient Results	Results Genova Diagnostics Commensal Bacteria Clinical Associat							
Commensal Bacteria	Out of Reference Range	IBS	IBD	Metabolic Syndrome	Chronic Fatigue	Auto- immune	Type 2 Diabetes	High Blood Pressure	Mood Disorders
Bacteroidetes Phylum									
Bacteroides-Prevotella group		†	†	†	†	†	†	†	†
Bacteroides vulgatus		↑			↑	↑		↑	†
Barnesiella spp.									
Odoribacter spp.									
Prevotella spp.	н	^		^	^	†		^	↑
Firmicutes Phylum									
Anaerotruncus colihominis	н	†	^	1	↑	†	†	†	†
Butyrivibrio crossotus	Н								
Clostridium spp.									
Coprococcus eutactus		†			^	^		^	^
Faecalibacterium prausnitzii		<u></u>				^			^
Lactobacillus spp.									
Pseudoflavonifractor spp.	н	†	^	^	^	^	^	^	^
Roseburia spp.	L		1						
Ruminococcus spp.	н	▼ ↑	1	1	1	▼ ↑	▼ ↑	▼ ↑	▼ ↑
Veillonella spp.	н	^	A	<u> </u>	<u></u>	↑	^		↑
Actinobacteria Phylum									
Bifidobacterium spp.									
Bifidobacterium longum									
Collinsella aerofaciens		▼ ↑	▼ ↑	1	₹ ↑	▼ ↑	▼ ↑	▼ ↑	▼ ↑
Proteobacteria Phylum			7.						
Desulfovibrio piger	н								^
Escherichia coli	Н Н	A	A	1	A	A	^	A	<u>,</u>
Oxalobacter formigenes	Н Н	<u>,</u>		<u> </u>	<u> </u>	· ·	<u> </u>		<u>,</u>
Euryarchaeota Phylum	11								
Methanobrevibacter smithii	н	^				†			†
Fusobacteria Phylum	11								
Fusobacterium spp.	н	^	†	†	†	†	†	†	^
Verrucomicrobia Phylum	11		<u> </u>					•	
Akkermansia muciniphila		1	Ţ	↓ ↓	Ţ	1	↓	T	Ţ
,									¥

*Information derived from GDX results data comparing a healthy cohort to various clinical condition cohorts. The chart above showing a comparison of patient results to clinical conditions is meant for informational purposes only; it is not diagnostic, nor does it imply that the patient has a specific clinical diagnosis or condition.

The arrows indicate Genova's clinical condition cohort test results falling below \downarrow or above \uparrow the reference range that is greater than that of Genova's healthy cohort.

Noticates Genova's clinical condition cohort test results falling below and above the reference range that are greater than that of Genova's healthy cohort.

Cells with bolded arrows indicate Genova's clinical condition cohort had more test results falling above versus below $\frac{1}{2}$ or more below versus above $\frac{1}{2}$ the reference range compared to that of Genova's healthy cohort.

2200 GI Effects™ Comprehensive Profile - Stool

Interpretation At-a-Glance									
	Patient Results	Results Genova Diagnostics Biomarker Clinical Association					ations*		
Biomarker	Out of Reference Range	IBS	IBD	Metabolic Syndrome	Chronic Fatigue	Auto- immune	Type 2 Diabetes	High Blood Pressure	Mood Disorders
Pancreatic Elastase	L	\	\	+	\	\	\	\	¥
Products of Protein Breakdown (Total)							↑ ↓		
Fecal Fat (Total*)		↑		↑	†	†	↓	†	†
Triglycerides		†			†	†	†	1	<u>†</u>
Long-Chain Fatty Acids		†			†	†	↓ ♠	1	†
Cholesterol							₩.	↑	
Phospholipids		↑	↑	†	†	†	↑	1	↑
Calprotectin	Н		↑					↑	
Eosinophil Protein X (EPX)	Н		↑						
Fecal secretory IgA		↑	↑	†	†	†	†	1	†
Short-Chain Fatty Acids (SCFA) (Total)					\	¥			
n-Butyrate Concentration				V					
n-Butyrate %									
Acetate %					↑ ↓		▼ ↑		
Propionate %				†			†	†	
Beta-glucuronidase						↑ ↓			↑ ↓

*Information derived from GDX results data comparing a healthy cohort to various clinical condition cohorts. The chart above showing a comparison of patient results to clinical conditions is meant for informational purposes only; it is not diagnostic, nor does it imply that the patient has a specific clinical diagnosis or condition.

The arrows indicate Genova's clinical condition cohort test results falling below

or above

↑ the reference range that is greater than that of Genova's healthy cohort

↑ Indicates Genova's clinical condition cohort test results falling below and above the reference range that are greater than that of Genova's healthy cohort.

Cells with bolded arrows indicate Genova's clinical condition cohort had more test results falling above versus below $\sqrt[4]{}$ or more below versus above $\sqrt[4]{}$ the reference range compared to that of Genova's healthy cohort.